<DOC>
	<DOCNO>NCT02925520</DOCNO>
	<brief_summary>This expand access study assess safety profile change serum direct bilirubin level infant PN associate cholestasis . Eligible patient receive therapy Omegaven expand access basis method continuous infusion . Omegaven infuse intravenously either central peripheral catheter conjunction parenteral nutrition . The standard care provide patient receive parenteral nutrition solution follow .</brief_summary>
	<brief_title>Expanded Access Use OmegavenÂ® Treatment Parenteral Nutrition Induced Liver Injury Children</brief_title>
	<detailed_description>This expand access protocol provide mechanism critically ill infant parenteral nutrition-associated liver disease ( PNALD ) receive Omegaven compassionate use situation satisfactory alternative treatment .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Greater 4 week ( 28 day ) old less 5 year age Diagnosis PNALD define serum direct bilirubin great 2 mg/dL 2 consecutive occasion Expected require intravenous nutrition least additional 28 day Have PNdependent least four week prior plan Omegaven initiation PNdependent unable meet nutritional requirement enteral mean Have fail standard therapy prevent progression PNALD Hospitalized time Omegaven initiation Have congenitally lethal condition ( e.g . Trisomy 13 ) . Have evidence viral hepatitis primary liver disease primary etiology cholestasis . Have health problem survival extremely unlikely even infant 's cholestasis improve . Have another clinical trial within 30 day prior enrollment received investigational drug within 30 day prior enrollment schedule receive investigational drug Omegaven study period . Severe and/or unstable concomitant systemic disease complex congenital cardiac disease , renal failure , autoimmune disease , sepsis , inborn error metabolism , genetic liver disease Bleeding disorder Biochemical disturbance potential worsening propose treatment , e.g . persistent hyperglycemia , hypertriglyceridemia , hypercalcemia .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Cholestasis</keyword>
</DOC>